+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

New rapid ecarin clotting time assay strongly correlates with bivalirudin concentration among percutaneous coronary intervention patients



New rapid ecarin clotting time assay strongly correlates with bivalirudin concentration among percutaneous coronary intervention patients



European Heart Journal 24(Abstract Suppl.): 195, August-September




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035389738

Download citation: RISBibTeXText


Related references

A new rapid ecarin clotting time assay but not activated clotting time strongly correlates with bivalirudin concentration A percutaneous coronary intervention study. Journal of the American College of Cardiology 39(5 Suppl. A): 17A, March 6, 2002

Measurement of patients' bivalirudin plasma levels by a thrombelastograph ecarin clotting time assay: a comparison to a standard activated clotting time. Anesthesia and Analgesia 102(5): 1316-1319, 2006

Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration. Thrombosis Research 113(2): 115-121, 2004

Ionic contrast substantially increases the activated clotting time in patients receiving abciximab and bivalirudin at the time of percutaneous coronary intervention. Journal of the American College of Cardiology 39(5 Suppl. A): 49A, March 6, 2002

Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention. American Journal of Cardiology 94(6): 789-792, 2004

Intracoronary macrothrombus formation during percutaneous coronary intervention despite optimal activated clotting time using bivalirudin--a case report. Angiology 56(6): 761-765, 2005

Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations. American Journal of Cardiology 91(9): 1110-1113, 2003

Dosage optimization of antithrombin drugs using ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization and percutaneous coronary interventions. Journal of Clinical Pharmacology 40(9): 1064, 2000

The association between activated clotting time and hemorrhagic complications in patients undergoing percutaneous coronary interventions with bivalirudin. Pharmacotherapy 23(10): 1330, 2003

Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. Anesthesia and Analgesia 96(2): 383-6, Table of Contents, 2003

Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial. Journal of the American College of Cardiology 45(12): 1932-1938, 2005

Utilization of ecarin clotting time as a global clotting assay for the monitoring of thrombin inhibitors. Clinical Chemistry 42(6 PART 2): S98, 1996